全文获取类型
收费全文 | 113篇 |
免费 | 2篇 |
专业分类
耳鼻咽喉 | 1篇 |
基础医学 | 21篇 |
临床医学 | 17篇 |
内科学 | 13篇 |
神经病学 | 3篇 |
特种医学 | 15篇 |
外科学 | 9篇 |
预防医学 | 17篇 |
眼科学 | 6篇 |
药学 | 11篇 |
肿瘤学 | 2篇 |
出版年
2022年 | 1篇 |
2021年 | 3篇 |
2019年 | 1篇 |
2018年 | 2篇 |
2016年 | 1篇 |
2015年 | 2篇 |
2014年 | 1篇 |
2012年 | 2篇 |
2011年 | 10篇 |
2010年 | 4篇 |
2009年 | 2篇 |
2008年 | 3篇 |
2007年 | 8篇 |
2006年 | 10篇 |
2005年 | 5篇 |
2004年 | 4篇 |
2003年 | 2篇 |
2002年 | 1篇 |
2001年 | 1篇 |
1999年 | 1篇 |
1998年 | 1篇 |
1996年 | 1篇 |
1992年 | 4篇 |
1991年 | 3篇 |
1990年 | 3篇 |
1989年 | 6篇 |
1988年 | 2篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 3篇 |
1973年 | 1篇 |
1971年 | 2篇 |
1969年 | 3篇 |
1968年 | 3篇 |
1967年 | 2篇 |
1966年 | 3篇 |
1965年 | 1篇 |
排序方式: 共有115条查询结果,搜索用时 15 毫秒
1.
2.
3.
The authors deal with the problem of clinical introduction of pharmacogenetic studies to individualize pharmacotherapy. On the basis of their own studies they propose the methodology of studying the clinical significance of pharmacogenetic studies of biotransformation system and drug transporters, and formulate the main requirements pharmacogenetic studies should meet to be introduced to clinical practice. 相似文献
4.
Alexey Sokolov Irina Isakova-Sivak Natalia Grudinina Daria Mezhenskaya Elena Litasova Valeria Kostevich Ekaterina Stepanova Alexandra Rak Ivan Sychev Olga Kirik Larisa Rudenko 《Viruses》2022,14(2)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to have a significant impact on global public health. Multiple mechanisms for SARS-CoV-2 cell entry have been described; however, the role of transferrin receptor 1 (TfR1) in SARS-CoV-2 infection has received little attention. We used ferristatin II to induce the degradation of TfR1 on the surface of Vero cells and to study the consequences of such treatment on the viability of the cells and the replication of SARS-CoV-2. We demonstrated that ferristatin II is non-toxic for Vero cells in concentrations up to 400 µM. According to confocal microscopy data, the distribution of the labeled transferrin and receptor-binding domain (RBD) of Spike protein is significantly affected by the 18h pretreatment with 100 µM ferristatin II in culture medium. The uptake of RBD protein is nearly fully inhibited by ferristatin II treatment, although this protein remains bound on the cell surface. The findings were well confirmed by the significant inhibition of the SARS-CoV-2 infection of Vero cells by ferristatin II with IC50 values of 27 µM (for Wuhan D614G virus) and 40 µM (for Delta virus). A significant reduction in the infectious titer of the Omicron SARS-CoV-2 variant was noted at a ferristatin II concentration as low as 6.25 µM. We hypothesize that ferristatin II blocks the TfR1-mediated SARS-CoV-2 host cell entry; however, further studies are needed to elucidate the full mechanisms of this virus inhibition, including the effect of ferristatin II on other SARS-CoV-2 receptors, such as ACE2, Neuropilin-1 and CD147. The inhibition of viral entry by targeting the receptor on the host cells, rather than the viral mutation-prone protein, is a promising COVID-19 therapeutic strategy. 相似文献
5.
6.
7.
Sychev DA Mikheeva IuA Kropacheva ES Ignat'ev IV Bulytova IuM Ramenskaia GV Dobrovol'skiĭ AB Panchenko EP Kukes VG 《Klinicheskaia meditsina》2007,85(1):57-60
CYP2C9 is the main enzyme participating in warfarin metabolism, of which genetic polymorphism is typical. The aim of the study was to investigate the influence of having allelic variants CYP2C9*2 and CYP2C9*3 on the pharmacokinetics, dosage regimen, and the rate of hemorrhage in patients with constant atrial fibrillation taking warfarin. Eighty-two patients with constant atrial fibrillation taking warfarin were included in the study. It was shown that in patients with CYP2C9*2 and CYP2C9*3 the clearance of warfarin and its dose were lower, while the episodes of excessive hypocoagulation and hemorrhage associated with warfarin were more frequent than in patients without these allelic variants. Basing on the results of the study, the authors propose an algorithm of choosing the initial warfarin dose depending on CYP2C9 genotype. 相似文献
8.
Lifshits IuZ Valetskiĭ VL Zaĭchenko PA Savitskiĭ RV Sychev VA Iarovoĭ AV 《Klinichna khirurhiia / Ministerstvo okhorony zdorov'ia Ukra?ny, Naukove tovarystvo khirurhiv Ukra?ny》2008,(6):24-26
Tactics and results of surgical treatment of 5 patients for splenic cyst were analyzed. The original method of splenic cyst resection, using blood-preserving technologies (ultrasonic aspirator-destructor, the argon laser and hemostatics) was applied. The data obtained permit to consider the splenic resection performance an adequate procedure for the focal organ pathology treatment. 相似文献
9.
On the basis of examination results and treatment of 49 patients with abdominal gunshot injuries the article emphasizes that the clinical picture of gunshot peritonitis develops much faster, and the syndrome of intoxication proceeds far harder, than in cases of peritonitis with another etiology. The authors make a conclusion that an early application of extracorporal methods of detoxication (hemosorption, plasmapheresis, ultraviolet irradiation of autologous blood, xenospleen connection) could minimize the level of intoxication and contribute to the correction of the immune status. 相似文献
10.
Belenkov IuN Skvortsov AA Mareev VIu Nasonova SN Sychev AV Narusov OIu Baklanova NA Masenko VP 《Kardiologiia》2003,43(10):10-21
The use of beta-adrenoblockers in conjunction with angiotensin converting enzyme inhibitors improves quality of life and prognosis of patients with chronic heart failure. However basic mechanisms of these positive effects in severe heart failure remain to be elucidated. METHODS: Patients (n=54) with NYHA class III-IV heart failure and left ventricular ejection fraction < or =35% were randomized either to treatment with bisoprolol (1.25-10 mg/day) (n=30) or in control group (n=24) and were followed up for 12 months. RESULTS: The use of bisoprolol was associated with significant improvement of heart failure functional class, lowering of heart rate (by 14%, p<0.01), elevation of systolic blood pressure (by 7.2+/-12.3 mm Hg, p<0.01) and increase of walking distance (by 30.1+/-29.0 m, p<0.01). No significant changes of these parameters occurred in control group. After 12 months increases of left ventricular end diastolic and end systolic volumes (by 85+/-69.2 and 71+/-51.5 ml, respectively, p<0.001) and of ejection fraction (by 5.7+/-7.3%, p<0.01) took place in bisoprolol treated patients. These changes were significantly (p<0.001) higher than those in control group. After 6 months of treatment with bisoprolol noradrenaline concentration fell from 533 to 402 pg/ml (p<0.05) while in controls it rose from 369 to 474 pg/ml, p<0.01). Decreases of plasma renin activity (from 1.2 to 0.42 ng/ml/h), plasma concentrations of angiotensin II (from 17.1 to 13.1 pg/ml) and aldosterone (from 173 to 148 pg/ml, p<0.05) were also observed in bisoprolol group. No substantial dynamics of activity of main components of renin angiotensin system took place in controls. There were no significant changes of atrial natriuretic peptide in both groups. Significant positive dynamics of parameters of heart rate variability was registered only in bisoprolol group: SDNN increased by 25% (p<0.05), high frequency spectrum by 106% (p=0.03), LF/HF ratio from 2.18+/-1.41 to 1.82+/-0.7. CONCLUSION: Long term use of bisoprolol was associated with improved clinical and hemodynamic status, increased systolic BP, blocked processes of pathological left ventricular remodeling, lowered activity of not only sympathetic-adrenal but also of main components of renin-angiotensin system and improved heart rate variability. 相似文献